Published in Z Kardiol on January 01, 2005
Appraisal tools for clinical practice guidelines: a systematic review. PLoS One (2013) 1.14
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA (2001) 17.91
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J (2003) 17.80
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J (2003) 8.51
Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation (2002) 6.20
Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J (2003) 3.55
Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart (1999) 3.53
Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J (2003) 3.48
Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J (2000) 2.90
A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol (2002) 2.77
An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health (2003) 1.96
AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol (1999) 1.92
Response to Conroy et al. SCORE Project. Eur Heart J (2003) 1.20
Comparative accuracy of cardiovascular risk prediction methods in primary care patients. Heart (2001) 0.91
[Cost-effectiveness of coronary heart disease prevention]. Z Kardiol (2002) 0.81
Is there a need for novel cardiovascular risk factors? Nephrol Dial Transplant (2004) 0.80
Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet (1999) 7.04
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis (1996) 2.70
Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol (1992) 2.57
Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis (1983) 2.37
The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res (1997) 2.14
High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol (2001) 2.03
KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet (1997) 1.90
Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res (1993) 1.85
Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol (2001) 1.80
Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem (1984) 1.77
Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem (1990) 1.75
A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A (1991) 1.69
C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J (2000) 1.63
Effect of sympathetic activity on capsaicin-evoked pain, hyperalgesia, and vasodilatation. Neurology (1999) 1.59
Defective peroxisomal catabolism of branched fatty acyl coenzyme A in mice lacking the sterol carrier protein-2/sterol carrier protein-x gene function. Genes Dev (1998) 1.58
A novel frameshift mutation in PMP22 accounts for hereditary neuropathy with liability to pressure palsies. Neurology (1997) 1.56
Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol (1996) 1.55
Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb (1994) 1.52
Swine lipoproteins and atherosclerosis. Changes in the plasma lipoproteins and apoproteins induced by cholesterol feeding. Biochemistry (1975) 1.50
Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem (1997) 1.50
D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J (1999) 1.48
Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Münster study. J Hypertens (1998) 1.48
Comparison of the reflectance method (Reflotron reflectance photometer) with the absorbance method (automatic analysers) for the determination of cholesterol. J Clin Chem Clin Biochem (1989) 1.48
Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men. Eur Heart J (2002) 1.47
Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease. Digestion (2010) 1.45
Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem (1983) 1.45
Plasminogen activator inhibitor-1 4G/4G-genotype is associated with cerebral sinus thrombosis in factor V Leiden carriers. Thromb Haemost (1998) 1.43
Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem (2001) 1.43
Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation (1997) 1.43
Identification of oxidized low-density lipoprotein in human serum by NMR spectroscopy. Clin Sci (Lond) (1998) 1.40
[Primary and secondary prevention of coronary heart disease. A position paper of the International Task Force for the Prevention of Coronary Heart Disease]. Dtsch Med Wochenschr (2000) 1.39
Arguments in favour of a homologous concept for hemodialysis access procedures. Feasibility and results. Eur J Vasc Endovasc Surg (2003) 1.39
Measurement of prostate-specific antigen: no advantage to ultrasensitive assays? J Natl Cancer Inst (1996) 1.39
The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J (1988) 1.38
Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res (1996) 1.37
Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol (1999) 1.34
Hind III RFLP in the lipoprotein lipase gene, (LPL). Nucleic Acids Res (1987) 1.32
The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J (1998) 1.31
Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure. J Biol Chem (1990) 1.31
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J (1999) 1.27
Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Münster. J Clin Endocrinol Metab (2000) 1.26
The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J (1998) 1.26
Pst I RFLP close to the LDL receptor gene. Nucleic Acids Res (1986) 1.26
The rat arginine-rich apoprotein and its redistribution following injection of iodinated lipoproteins into normal and hypercholesterolemic rats. Atherosclerosis (1977) 1.24
Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPARalpha) in sterol carrier protein 2-/ sterol carrier protein x-deficient mice. J Biol Chem (1999) 1.21
Sterol carrier protein X is peroxisomal 3-oxoacyl coenzyme A thiolase with intrinsic sterol carrier and lipid transfer activity. J Biol Chem (1994) 1.19
Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol (2000) 1.18
Endogenous apolipoprotein E modulates cholesterol efflux and cholesteryl ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages. J Mol Med (Berl) (2000) 1.18
The LQT syndromes--current status of molecular mechanisms. Z Kardiol (1999) 1.18
Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem (1986) 1.17
Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem (1998) 1.17
Lipid-protein interactions in high density lipoproteins. Proc Natl Acad Sci U S A (1974) 1.17
A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest (1991) 1.16
Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III. J Lipid Res (1991) 1.16
Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM). Atherosclerosis (1999) 1.15
Genotype/phenotype relationships in HNF-4alpha/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels. Diabetes (2000) 1.15
Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest (1991) 1.15
Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest (2007) 1.15
Characterization, subcellular localization, and partial purification of a heparin-released triglyceride lipase from rat liver. J Biol Chem (1973) 1.14
Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost (1985) 1.14
Isolation and characterization of an abnormal high density lipoprotein in Tangier Diesase. J Clin Invest (1977) 1.13
A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A (1994) 1.13
Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer (1998) 1.12
The lipoprotein abnormality in Tangier disease: quantitation of A apoproteins. J Clin Invest (1977) 1.12
Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. J Lipid Res (1999) 1.11
The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem Biophys Res Commun (1994) 1.10
Effect of pathogen-specific clinical mastitis on milk yield in dairy cows. J Dairy Sci (2004) 1.10
Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT). Eur Heart J (1999) 1.10
An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease). J Clin Invest (1996) 1.08
Acceleration of reverse cholesterol transport. Curr Opin Cardiol (2000) 1.08
Serum ferritin, transferrin, haptoglobin, and iron in middle- and long-distance runners, elite rowers, and professional racing cyclists. Int J Sports Med (1981) 1.07
Polymorphisms in the apolipoprotein AI-CIII gene complex. Mol Biol Med (1986) 1.07
Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 1.06
Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation (1999) 1.05
Simplified turbidimetric determination of apolipoproteins A-I, A-II and B using a microtitre method. J Clin Chem Clin Biochem (1988) 1.04
Aberrant oxidation of the cholesterol side chain in bile acid synthesis of sterol carrier protein-2/sterol carrier protein-x knockout mice. J Biol Chem (1999) 1.04
The relationship of lipoprotein (a) (Lp(a)) to risk factors of coronary heart disease: initial results of the prospective epidemiological study on company employees in Westfalia. J Clin Chem Clin Biochem (1984) 1.04
Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol (1995) 1.03
Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3. Scand J Rheumatol (2005) 1.02
Plasma lipoproteins and physical activity: a review. Int J Sports Med (1982) 1.02
A molecular model of high density lipoproteins. Proc Natl Acad Sci U S A (1974) 1.02